CE for Nurses

In the past decade, the treatment landscape for multiple myeloma (MM) has significantly improved with the introduction of several novel treatment regimens. Oncology nurses are constantly challenged to stay up-to-date with these recent advances in the management of MM.

Frontline Treatment in Multiple Myeloma: Treating the Individual Patient
Frontline Treatment in Multiple Myeloma: Treating the Individual Patient
CNE
R. Donald Harvey, III, PharmD, BCOP, FCCP, FHOPA and Sagar Lonial, MD, FACP
Release Date: January 10, 2018
Expiration Date: January 10, 2019

In recent years, advances in treatment have resulted in significantly improved outcomes and prognoses in patients with multiple myeloma; much of this research, however, was focused on the population of patients with relapsed or refractory disease. Today, a growing compendium of data and ongoing research is evaluating treatment options and management approaches specifically in patients with newly diagnosed multiple myeloma. The addition of new lenalidomide- and bortezomib-based drug regimens for patients with multiple myeloma increases the complexity of pharmacotherapeutic strategies, which must balance response benefit with tolerability. In addition, there are a number of comorbidities and treatment-related adverse events that must be appropriately assessed and monitored for, to ensure patient safety and prevent premature discontinuation of therapy. In these activities, Dr. Lonial and Dr. Harvey provide an overview of the current and emerging frontline treatment paradigms for multiple myeloma, and discuss how to provide individualized care for patients with comorbid conditions.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology
Begin, Earn CreditView Only, No Credit